IMD-2128 / Affinity Biopharma - LARVOL DELTA

Novel ALDC and ADC with TMEAlinker and eribulin payload demonstrate excellent safety and efficacy in preclinical evaluation (AACR 2026) - "TMEAlinkers (TME-activated linkers) are legumain-activated linkers with clinical proof-of-concept (POC) from the phase 3 study of legubicin (an albumin drug conjugate, ALDC)...In cynomolgus monkeys, IMD2128 was well tolerated with a highest nonseverely toxic dose (HNSTD) over 16 mg/kg, showing a superior safety profile compared to VC linker-eribulin based ADCs (e.g., MORAb-202, HNSTD = 1.95 mg/kg). Pharmacokinetic studies in monkeys revealed a Cmax of 291.07 µmol/mL for IMD2128 ADC versus a Cmax of 0.0000823 µmol/mL for free eribulin (Cmax ratio ≈ 3.54 × 10⁶ : 1), confirming strong linker stability in circulation. Together, these findings highlight the versatility of the TMEAlinker platform for developing both ALDCs and ADCs with eribulin payloads, demonstrating excellent safety and efficacy in preclinical evaluations."

ADC • Preclinical • Oncology • Pancreatic Cancer • Solid Tumor • EGFR • LGMN • MET